New Clinical Trial Opportunity

- **Frontotemporal Dementia (FTD)**

SiteRx is excited to announce the launch of a new clinical research study in partnership with Prevail Therapeutics Inc. Now available to all network providers

PRV-FTD101 is a Phase I/II rare disease gene therapy trial

Clinical Trial Summary

- Limited Enrollment: Enrollment target (n=15)
- Medications: PR006 with methylprednisolone, sirolimus, prednisone
- **Exclusive SiteRx benefit**: All referred patients receive complementary progranulin genetic testing from the comfort of home
- Travel expenses for patients and caregiver paid for by sponsor
- Study duration: 5-years

Key Inclusion Criteria

- Has symptomatic frontotemporal dementia (FTD) – **ICD-10 G31.0**
- Carrier of a pathogenic GRN (progranulin gene) mutation
- Age and gender appropriate cancer screenings are up to date
- Patient is not dependent on a walker or wheelchair

Key Exclusion Criteria

- Diagnosis of a significant CNS (central nervous system) disease other than frontotemporal dementia (FTD) that may cause FTD symptoms or confound study objectives
- Brain magnetic resonance image (MRI) / magnetic resonance angiography (MRA) showing clinically significant abnormality considered to prevent intracisternal injection

Questions about PVR-FTD101?

Contact your Clinical Trial Advocate Today: Hello@SiteRx.com

Immediate Patient Need

15

PRV-FTD101 is available to a limited number of patients and offers a new gene therapy treatment

Patient Site Options

3

SiteRx is launching PRV-FTD101 at sites in California, Florida, and Pennsylvania – with national airfare and travel covered!